{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T05:50:08Z","timestamp":1791957008689,"version":"4.3.4"},"reference-count":79,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>To review recent literature with relevance to the management of multimorbid patients with gout, i.e., gout medication repurposed for comorbidities and vice versa.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Adding to the previous success of interleukin-1 inhibition, two trials on low-dose colchicine's role in cardiovascular disease (CVD) demonstrated potential benefits in patients with or without gout. In Colchicine Cardiovascular Outcomes Trial, a composite CVD endpoint was reduced by 23% among patients who had experienced a recent myocardial infarction. In Low-Dose Colchicine 2, the composite CVD endpoint was reduced 31% among those with stable coronary artery disease. Use of urate-lowering therapy (ULT) for renal protection in patients without gout produced null results. Allopurinol did not benefit the glomerular filtration rate in two trials (Controlled trial of slowing of Kidney Disease progression From the Inhibition of Xanthine oxidase and Preventing Early Renal Function Loss) among patients with chronic kidney disease (with or without hyperuricemia, but not gout). SGLT-2 inhibitors, a medication recommended for patients with diabetes and CVD, diabetic kidney disease, or heart failure, demonstrated a protective effect against gout flares in a secondary trial analysis and a large observational study.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>The role of colchicine may expand beyond gout flare prevention to patients with existing CVD. The renal benefit of ULT among patients with gout remains unclear. SGLT-2 inhibitors may benefit diabetic patients who have gout as a comorbidity.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000000784","type":"journal-article","created":{"date-parts":[[2021,1,5]],"date-time":"2021-01-05T06:02:56Z","timestamp":1609826576000},"page":"145-154","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Medications for gout and its comorbidities: mutual benefits?"],"prefix":"10.1097","volume":"33","author":[{"given":"Kazuki","family":"Yoshida","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women's Hospital"},{"name":"Harvard Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyon K.","family":"Choi","sequence":"additional","affiliation":[{"name":"Harvard Medical School"},{"name":"Division of Rheumatology, Allergy & Immunology, Department of Medicine, Massachusetts General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel H.","family":"Solomon","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women's Hospital"},{"name":"Harvard Medical School"},{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,1,4]]},"reference":[{"key":"R1-20250526","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3109\/13814789609162146","article-title":"Comorbidity or multimorbidity","volume":"2","author":"Akker","year":"1996","journal-title":"Eur J Gen Pract"},{"key":"R2-20250526","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrrheum.2013.212","article-title":"Multimorbidity and rheumatic conditions-enhancing the concept of comorbidity","volume":"10","author":"Radner","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"R3-20250526","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.amjmed.2011.09.033","article-title":"Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008","volume":"125","author":"Zhu","year":"2012","journal-title":"Am J Med"},{"key":"R4-20250526","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/BOR.0000000000000691","article-title":"Comorbidities in gout and hyperuricemia: causality or epiphenomena?","volume":"32","author":"Sumpter","year":"2020","journal-title":"Curr Opin Rheumatol"},{"key":"R5-20250526","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/art.41247","article-title":"2020 American College of Rheumatology Guideline for the Management of Gout","volume":"72","author":"FitzGerald","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"R6-20250526","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jacc.2012.10.027","article-title":"Low-dose colchicine for secondary prevention of cardiovascular disease","volume":"61","author":"Nidorf","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"R7-20250526","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"R8-20250526","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N Engl J Med"},{"key":"R9-20250526","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"N Engl J Med"},{"key":"R10-20250526","first-page":"174","article-title":"Closing the loop on inflammation and atherothrombosis: why perform the CIRT and CANTOS trials?","volume":"124","author":"Ridker","year":"2013","journal-title":"Trans Am Clin Climatol Assoc"},{"key":"R11-20250526","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s11883-012-0295-3","article-title":"Moving beyond JUPITER: will inhibiting inflammation reduce vascular event rates?","volume":"15","author":"Ridker","year":"2013","journal-title":"Curr Atheroscler Rep"},{"key":"R12-20250526","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1161\/CIRCRESAHA.115.306656","article-title":"From C-reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection","volume":"118","author":"Ridker","year":"2016","journal-title":"Circ Res"},{"key":"R13-20250526","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1056\/NEJMe1709904","article-title":"Targeting inflammation in coronary artery disease","volume":"377","author":"Harrington","year":"2017","journal-title":"N Engl J Med"},{"key":"R14-20250526","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/nature08938","article-title":"NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals","volume":"464","author":"Duewell","year":"2010","journal-title":"Nature"},{"key":"R15-20250526","doi-asserted-by":"crossref","first-page":"e11765","DOI":"10.1371\/journal.pone.0011765","article-title":"Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation","volume":"5","author":"Rajam\u00e4ki","year":"2010","journal-title":"PLoS One"},{"key":"R16-20250526","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature04516","article-title":"Gout-associated uric acid crystals activate the NALP3 inflammasome","volume":"440","author":"Martinon","year":"2006","journal-title":"Nature"},{"key":"R17-20250526","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4161\/mabs.2.1.10328","article-title":"Canakinumab","volume":"2","author":"Dhimolea","year":"2010","journal-title":"MAbs"},{"key":"R18-20250526","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1002\/art.27600","article-title":"Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study","volume":"62","author":"So","year":"2010","journal-title":"Arthritis Rheumatol"},{"key":"R19-20250526","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1111\/ijcp.12521","article-title":"Efficacy of Canakinumab vs. triamcinolone acetonide according to multiple gouty arthritis-related health outcomes measures","volume":"68","author":"Hirsch","year":"2014","journal-title":"Int J Clin Pract"},{"key":"R20-20250526","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1136\/annrheumdis-2011-200908","article-title":"Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions","volume":"71","author":"Schlesinger","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"R21-20250526","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/ar3297","article-title":"Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study","volume":"13","author":"Schlesinger","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"R22-20250526","doi-asserted-by":"crossref","first-page":"535","DOI":"10.7326\/M18-1167","article-title":"Relationship of interleukin-1\u03b2 blockade with incident gout and serum uric acid levels: exploratory analysis of a randomized controlled trial","volume":"169","author":"Solomon","year":"2018","journal-title":"Ann Intern Med"},{"key":"R23-20250526","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1001\/jamacardio.2018.4566","article-title":"Cost-effectiveness of Canakinumab for prevention of recurrent cardiovascular events","volume":"4","author":"Sehested","year":"2019","journal-title":"JAMA Cardiol"},{"key":"R25-20250526","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/MOL.0000000000000552","article-title":"Colchicine: an affordable anti-inflammatory agent for atherosclerosis","volume":"29","author":"Thompson","year":"2018","journal-title":"Curr Opin Lipidol"},{"key":"R26-20250526","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s11883-020-00883-3","article-title":"Targeting inflammation to reduce residual cardiovascular risk","volume":"22","author":"Ajala","year":"2020","journal-title":"Curr Atheroscler Rep"},{"key":"R27-20250526","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1136\/ard.13.3.190","article-title":"History of the use of colchicum and related medicaments in gout; with suggestions for further research","volume":"13","author":"Hartung","year":"1954","journal-title":"Ann Rheum Dis"},{"key":"R28-20250526","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/j.clinthera.2014.07.017","article-title":"Mechanism of action of colchicine in the treatment of gout","volume":"36","author":"Dalbeth","year":"2014","journal-title":"Clin Ther"},{"key":"R29-20250526","doi-asserted-by":"crossref","first-page":"684","DOI":"10.2174\/1381612824999180115103951","article-title":"Colchicine in gout: an update","volume":"24","author":"Pascart","year":"2018","journal-title":"Curr Pharm Des"},{"key":"R30-20250526","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1002\/art.22938","article-title":"The role of interleukin-1 and the inflammasome in gout: implications for therapy","volume":"56","author":"Pope","year":"2007","journal-title":"Arthritis Rheumatol"},{"key":"R31-20250526","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41572-019-0115-y","article-title":"Gout","volume":"5","author":"Dalbeth","year":"2019","journal-title":"Nat Rev Dis Prim"},{"key":"R32-20250526","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1016\/j.jacc.2017.09.028","article-title":"Interleukin-1 beta as a target for atherosclerosis therapy: biological basis of CANTOS and beyond","volume":"70","author":"Libby","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"R33-20250526","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1161\/CIRCULATIONAHA.120.050771","article-title":"Colchicine in patients with acute coronary syndrome: The Australian COPS Randomized Clinical Trial","volume":"142","author":"Tong","year":"2020","journal-title":"Circulation"},{"key":"R34-20250526","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1136\/annrheumdis-2015-207984","article-title":"Effects of colchicine on risk of cardiovascular events and mortality among patients with gout: a cohort study using electronic medical records linked with Medicare claims","volume":"75","author":"Solomon","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R35-20250526","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1136\/heartjnl-2015-308542","article-title":"Cardiovascular effects and safety of long-term colchicine treatment: cochrane review and meta-analysis","volume":"102","author":"Hemkens","year":"2016","journal-title":"Heart"},{"key":"R36-20250526","first-page":"1","article-title":"Cost-effectiveness of low-dose colchicine after myocardial infarction in the colchicine cardiovascular outcomes trial (COLCOT)","author":"Samuel","year":"2020","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"R37-20250526","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1053\/j.ajkd.2010.01.019","article-title":"Association of uric acid with change in kidney function in healthy normotensive individuals","volume":"56","author":"Bellomo","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"R38-20250526","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1053\/j.ajkd.2007.05.013","article-title":"Relationship of uric acid with progression of kidney disease","volume":"50","author":"Chonchol","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"R39-20250526","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1681\/ASN.2007101075","article-title":"Uric acid and incident kidney disease in the community","volume":"19","author":"Weiner","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"R40-20250526","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1681\/ASN.2008010080","article-title":"Elevated uric acid increases the risk for kidney disease","volume":"19","author":"Obermayr","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"R41-20250526","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.jdiacomp.2016.06.002","article-title":"Hyperuricemia contributes to the faster progression of diabetic kidney disease in type 2 diabetes mellitus","volume":"30","author":"Bart\u00e1kov\u00e1","year":"2016","journal-title":"J Diabetes Complicat"},{"key":"R42-20250526","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1093\/ndt\/gft378","article-title":"Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis","volume":"29","author":"Bose","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"R43-20250526","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1093\/eurheartj\/ehz119","article-title":"Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy","volume":"40","author":"Kojima","year":"2019","journal-title":"Eur Heart J"},{"key":"R44-20250526","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1056\/NEJMoa1915833","article-title":"Effects of allopurinol on the progression of chronic kidney disease","volume":"382","author":"Badve","year":"2020","journal-title":"N Engl J Med"},{"key":"R45-20250526","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1056\/NEJMoa1916624","article-title":"Serum urate lowering with allopurinol and kidney function in type 1 diabetes","volume":"382","author":"Doria","year":"2020","journal-title":"N Engl J Med"},{"key":"R46-20250526","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1124\/pr.58.1.6","article-title":"Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol","volume":"58","author":"Pacher","year":"2006","journal-title":"Pharmacol Rev"},{"key":"R48-20250526","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1681\/ASN.2009010025","article-title":"Change in estimated GFR associates with coronary heart disease and mortality","volume":"20","author":"Matsushita","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"R49-20250526","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1136\/annrheumdis-2015-208237","article-title":"2015 Gout classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"74","author":"Neogi","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"R50-20250526","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s11906-017-0793-3","article-title":"The effect of xanthine oxidase inhibitors on blood pressure and renal function","volume":"19","author":"Bove","year":"2017","journal-title":"Curr Hypertens Rep"},{"key":"R51-20250526","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJM198707163170304","article-title":"Equipoise and the ethics of clinical research","volume":"317","author":"Freedman","year":"1987","journal-title":"N Engl J Med"},{"key":"R52-20250526","first-page":"1689","article-title":"Allopurinol and Chronic Kidney Disease","volume":"383","author":"McCormick","year":"2020","journal-title":"N Engl J Med"},{"key":"R53-20250526","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","article-title":"Cardiovascular safety of febuxostat or allopurinol in patients with gout","volume":"378","author":"White","year":"2018","journal-title":"N Engl J Med"},{"key":"R54-20250526","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1002\/art.40583","article-title":"New perspectives in rheumatology: implications of the cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular morbidities trial and the Associated Food and Drug Administration Public Safety Alert","volume":"70","author":"Choi","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"R55-20250526","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.jacc.2017.12.052","article-title":"Cardiovascular risks of probenecid versus allopurinol in older patients with gout","volume":"71","author":"Kim","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"R56-20250526","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1002\/art.40486","article-title":"Allopurinoldose escalation and mortality among patients with gout: A National Propensity-Matched Cohort Study","volume":"70","author":"Coburn","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"R57-20250526","article-title":"Mortality in patients with gout treated with allopurinol: a systematic review and meta-analysis","author":"Hay","year":"2020","journal-title":"Arthritis Care Res"},{"key":"R58-20250526","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.lfs.2004.10.031","article-title":"Selectivity of febuxostat, a novel nonpurine inhibitor of xanthine oxidase\/xanthine dehydrogenase","volume":"76","author":"Takano","year":"2005","journal-title":"Life Sci"},{"issue":"(4 Suppl 2)","key":"R59-20250526","first-page":"S44","article-title":"An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a nonpurine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 2 exploratory clinical study","volume":"17","author":"Kamatani","year":"2011","journal-title":"J Clin Rheumatol"},{"key":"R60-20250526","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1007\/s10067-019-04893-8","article-title":"Evaluation of urate-lowering therapy in hyperuricemia patients: a systematic review and Bayesian network meta-analysis of randomized controlled trials","volume":"39","author":"Lin","year":"2020","journal-title":"Clin Rheumatol"},{"key":"R62-20250526","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/S0140-6736(20)32234-0","article-title":"Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial","volume":"396","author":"Mackenzie","year":"2020","journal-title":"Lancet"},{"key":"R63-20250526","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1053\/j.ajkd.2018.06.028","article-title":"Febuxostat therapy for patients with Stage 3 CKD and asymptomatic hyperuricemia: a randomized trial","volume":"72","author":"Kimura","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"R64-20250526","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1161\/HYPERTENSIONAHA.111.171488","article-title":"Effect of a reduction in uric acid on renal outcomes during losartan treatment","volume":"58","author":"Miao Yan","year":"2011","journal-title":"Hypertension"},{"key":"R65-20250526","doi-asserted-by":"crossref","first-page":"d8190","DOI":"10.1136\/bmj.d8190","article-title":"Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study","volume":"344","author":"Choi","year":"2012","journal-title":"BMJ"},{"key":"R66-20250526","doi-asserted-by":"crossref","first-page":"16767","DOI":"10.1038\/s41598-018-35175-z","article-title":"Effect of fenofibrate on uric acid level in patients with gout","volume":"8","author":"Jung","year":"2018","journal-title":"Sci Rep"},{"key":"R67-20250526","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S2213-8587(18)30029-9","article-title":"Effect of fenofibrate on uric acid and gout in type 2 diabetes: a post-hoc analysis of the randomised, controlled FIELD study","volume":"6","author":"Waldman","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R68-20250526","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.2337\/dc20-1002","article-title":"Effects of low-fat, mediterranean, or low-carbohydrate weight loss diets on serum urate and cardiometabolic risk factors: a secondary analysis of the Dietary Intervention Randomized Controlled Trial (DIRECT)","volume":"43","author":"Yokose","year":"2020","journal-title":"Diabetes Care"},{"key":"R69-20250526","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa0708681","article-title":"Weight loss with a low-carbohydrate, mediterranean, or low-fat diet","volume":"359","author":"Shai","year":"2008","journal-title":"N Engl J Med"},{"key":"R70-20250526","doi-asserted-by":"crossref","first-page":"e220","DOI":"10.1016\/S2665-9913(19)30078-5","article-title":"The effects of canagliflozin on gout in type 2 diabetes: a posthoc analysis of the CANVAS Program","volume":"1","author":"Li","year":"2019","journal-title":"Lancet Rheumatol"},{"key":"R71-20250526","doi-asserted-by":"crossref","first-page":"186","DOI":"10.7326\/M19-2610","article-title":"Assessing the risk for gout with sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: a population-based cohort study","volume":"172","author":"Fralick","year":"2020","journal-title":"Ann Intern Med"},{"key":"R72-20250526","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1111\/dom.13670","article-title":"Uric acid and the cardio-renal effects of SGLT2 inhibitors","volume":"21","author":"Bailey","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"R73-20250526","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijerph16162965","article-title":"SGLT2 inhibitors: a review of their antidiabetic and cardioprotective effects","volume":"16","author":"Tentolouris","year":"2019","journal-title":"Int J Environ Res Public Health"},{"key":"R75-20250526","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/dom.13101","article-title":"Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: a meta-analysis of randomized controlled trials","volume":"20","author":"Zhao","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"R76-20250526","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/bdd.1909","article-title":"SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria","volume":"35","author":"Chino","year":"2014","journal-title":"Biopharm Drug Dispos"},{"key":"R77-20250526","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"R78-20250526","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ahj.2013.05.007","article-title":"Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS) \u2013 a randomized placebo-controlled trial","volume":"166","author":"Neal","year":"2013","journal-title":"Am Heart J"},{"key":"R79-20250526","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/dom.12829","article-title":"Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial","volume":"19","author":"Neal","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"R80-20250526","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nrrheum.2015.30","article-title":"Active-comparator design and new-user design in observational studies","volume":"11","author":"Yoshida","year":"2015","journal-title":"Nat Rev Rheumatol"},{"key":"R81-20250526","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1111\/dom.13223","article-title":"Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and kidney clearance: Posthoc analyses of four clinical trials","volume":"20","author":"Tonneijck","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"(Supplement_1)","key":"R82-20250526","doi-asserted-by":"crossref","first-page":"i43","DOI":"10.1093\/ndt\/gfz292","article-title":"Sodium-glucose cotransporter 2 inhibitor effects on cardiovascular outcomes in chronic kidney disease","volume":"35","author":"Shivakumar","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"R83-20250526","doi-asserted-by":"crossref","first-page":"E197","DOI":"10.1016\/S2665-9913(19)30108-0","article-title":"Repurposing antidiabetic medications for gout: the potential of sodium glucose co-transporter 2 inhibitors","volume":"1","author":"Neogi","year":"2019","journal-title":"Lancet Rheumatol"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000784","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T21:22:16Z","timestamp":1748294536000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000784"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,4]]},"references-count":79,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000784","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,4]]}}}